Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Analysts weigh Bristol Myers Squibb’s $1.5bn Orbital Therapeutics deal as a bold but risky pivot
Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics aims to advance in vivo CAR T for autoimmune diseases and strengthen its RNA platform.
Can Protagonist’s icotrokinra become the first oral IL-23 therapy to rival biologics in ulcerative colitis?
Positive Phase 2b data for Protagonist Therapeutics’ oral IL-23R inhibitor icotrokinra show strong efficacy and safety in ulcerative colitis; learn what’s next for Phase 3.
Wall Street reacts as Johnson & Johnson circles Protagonist Therapeutics in a potential multibillion-dollar buyout
Explore how Johnson & Johnson’s bid to acquire Protagonist Therapeutics could reshape its immunology and hematology pipeline—details inside.
OS Therapies reports statistically significant 75% two-year survival with OST-HER2, eyes 2026 FDA approval
Find out how OS Therapies’ OST-HER2 achieved 75 % two-year survival in osteosarcoma and could secure FDA approval by 2026.
Quoin Pharmaceuticals raises up to $104.5M in private placement to fuel its rare disease pipeline
Find out how Quoin Pharmaceuticals secured up to $104.5 million in a milestone-linked private placement to advance its rare disease therapy QRX003 and strengthen investor confidence.
Inside Shuttle Pharmaceuticals’ $10m AI gamble: How Molecule.ai could rewrite drug discovery timelines
Shuttle Pharmaceuticals to acquire Molecule.ai for $10M, entering AI-driven drug discovery. See how this bold move could reshape SHPH’s biotech future.
Shuttle to enter $3.24bn AI pharmaceutical market via acquisition of Molecule.ai
Find out how Shuttle Pharmaceuticals’ $10 million acquisition of Molecule.ai could reshape its R&D strategy and redefine the $3.24 billion AI pharma landscape.
Cabaletta Bio’s rese-cel CAR-T data at ESGCT 2025 reveal biologic activity without preconditioning in autoimmune disease
Cabaletta Bio’s ESGCT 2025 rese-cel data show early CAR-T activity without chemotherapy preconditioning — see how this could redefine autoimmune therapy.
From GLP-1 to FGF21: How Novo Nordisk’s Akero Therapeutics deal signals a new era in metabolic drug dominance
Novo Nordisk’s $5.2 B Akero deal adds the FGF21 drug efruxifermin to its MASH portfolio. See how it expands the company’s metabolic dominance.
FDA approves Ligand Partner SQ Innovation’s Lasix ONYU for heart failure edema—at-home use marks major shift in care
Find out how Ligand and SQ Innovation’s FDA-approved Lasix ONYU is redefining heart-failure treatment with the first at-home edema therapy.